Binx Health secured $65M in series F financing led by Hildred Capital and EQT Life Sciences Partner to fuel its growth

Apr 04, 2024•over 1 year ago

Amount Raised

$65 Million

Round Type

series f

CambridgeMedicalBiotechnologyHealth Care

Investors

Eqt Life Sciences PartnerHildred Capital

Description

Binx Health has raised $65 million in series F financing to support commercial sales and high-volume manufacturing of its point-of-care molecular platform for diagnosing chlamydia and gonorrhea. The funding includes equity, debt, and expanded lease facility financing.

Company Information

Company

binx health Ltd

Location

245 First St, Riverview II, 18th Floor

Cambridge, Massachusetts, United States

About

Binx Health is a health technology company aiming to speed up the time between diagnosis and treatment of sexually transmitted infections with a point-of-care diagnostic solution. The company developed the Binx io point-of-care molecular platform, an FDA-cleared, CLIA-waived system, that can be used in doctors' offices, urgent care clinics and hospital emergency rooms to quickly diagnose chlamydia and gonorrhea for both men and women. Binx's point-of-care platform makes STI testing more convenient, accessible and discreet for patients.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends